Tempus AI CEO Lefkofsky sells shares worth $10.5 million
#Tempus AI #Eric Lefkofsky #Insider Sales #10b5-1 Trading Plan #Healthcare Technology #Stock Market #Medical Diagnostics
📌 Key Takeaways
- Tempus AI CEO Eric P. Lefkofsky sold $10.5 million worth of company shares on February 19, 2026
- The sales were executed under a pre-scheduled 10b5-1 trading plan at prices between $58.31-$59.70
- Despite the sale, Lefkofsky remains the largest shareholder with direct and indirect ownership
- The stock has gained 12% over the past week but is still 44% below its 52-week high
📖 Full Retelling
🏷️ Themes
Insider Trading, Healthcare Technology, Stock Market Performance
📚 Related People & Topics
Eric Lefkofsky
American billionaire businessman (born 1969)
Eric Paul Lefkofsky (born September 2, 1969) is an American billionaire businessman. He is the founder and CEO of Tempus AI, and the co-founder of Groupon, Echo Global Logistics (ECHO), InnerWorkings (INWK), and Mediaocean. As of June 2024, he is also a co-managing partner of Chicago-based venture ...
Tempus AI
American health technology company
Tempus AI, Inc. (formerly Tempus Labs) is an American health technology company founded in 2015 by Eric Lefkofsky in Chicago, Illinois. It was established by Lefkofsky soon after his wife was diagnosed with breast cancer.
Stock market
Place where stocks are traded
# Stock Market A **stock market**, also referred to as an **equity market** or **share market**, is the complex aggregation of buyers and sellers of stocks (shares). These financial instruments represent ownership claims on businesses and serve as a primary vehicle for capital allocation and corpor...
Entity Intersection Graph
No entity connections available yet for this article.
Deep Analysis
Why It Matters
The sale of $10.5 million in shares by Tempus AI CEO Eric Lefkofsky highlights insider activity amid a stock that has fallen 44 percent from its 52‑week high, raising questions about the company’s valuation and future prospects.
Context & Background
- CEO sold shares under a 10b5-1 trading plan
- TEM stock trading at $58.37, down 44 percent from its 52‑week high
- TEM announced new AI‑driven cancer detection algorithms
What Happens Next
Investors will watch the company’s earnings on February 24 for guidance on revenue and product adoption. Analysts may revise their price targets as the market evaluates the impact of the new AI tools and the company’s valuation relative to its fair value estimate.
Frequently Asked Questions
The sale was executed under a 10b5-1 trading plan, a routine transaction that also covered tax obligations related to restricted stock units.
The sale is unlikely to cause a significant immediate price movement; however, it may influence investor perception of insider confidence and the company’s valuation.